GW-501516 GlaxoSmithKline/Ligand

Curr Opin Investig Drugs. 2006 Apr;7(4):360-70.

Abstract

GlaxoSmithKline and Ligand are developing GW-501516, a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Phase II clinical trials of this compound are ongoing.

Publication types

  • Review

MeSH terms

  • Animals
  • Fatty Acids / metabolism
  • Glucose / metabolism
  • Humans
  • Hypolipidemic Agents / pharmacology*
  • Macaca mulatta
  • Mice
  • Mice, Obese
  • PPAR delta / drug effects
  • PPAR delta / physiology
  • Structure-Activity Relationship
  • Thiazoles / chemical synthesis
  • Thiazoles / pharmacology*
  • Thiazoles / therapeutic use

Substances

  • Fatty Acids
  • GW 501516
  • Hypolipidemic Agents
  • PPAR delta
  • Thiazoles
  • Glucose